Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases
- PMID: 9291299
- DOI: 10.1086/514074
Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases
Abstract
In the era before antibiotics, human diseases were commonly treated with immune animal and human sera, often with life-saving results. With the advent of emerging infectious diseases, many of which cannot be adequately treated or prevented, attempts to develop antibody treatments have taken on new importance. The role of humoral immunity in treatment and prevention was the focus of discussion at a 1996 workshop. The cellular and molecular mechanisms of neutralization were examined in detail. It was noted that success in passive immunity has frequently been the key element in devising a successful strategy to develop a vaccine for active immunization. The workshop concluded on a cautious note of optimism that antibody-based treatment and prevention for diseases such as human immunodeficiency virus infection, Ebola fever, and others of clinical and public health importance deserve further development and clinical trial.
Similar articles
-
Humoral immunity to HIV, SIV, and SHIV.AIDS. 1998;12 Suppl A:S121-32. AIDS. 1998. PMID: 9632993 Review. No abstract available.
-
Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.J Virol. 2003 Oct;77(19):10348-56. doi: 10.1128/jvi.77.19.10348-10356.2003. J Virol. 2003. PMID: 12970419 Free PMC article.
-
Prospects for vaccine protection against HIV-1 infection and AIDS.Annu Rev Immunol. 2002;20:73-99. doi: 10.1146/annurev.immunol.20.081501.094854. Epub 2001 Oct 4. Annu Rev Immunol. 2002. PMID: 11861598 Review.
-
Passive immunization of rhesus macaques against SIV infection and disease.AIDS Res Hum Retroviruses. 1995 Jul;11(7):843-54. doi: 10.1089/aid.1995.11.843. AIDS Res Hum Retroviruses. 1995. PMID: 7546912
-
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.J Virol. 2016 May 12;90(11):5315-5328. doi: 10.1128/JVI.00230-16. Print 2016 Jun 1. J Virol. 2016. PMID: 27009957 Free PMC article.
Cited by
-
Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.J Virol. 2002 Jul;76(13):6643-51. doi: 10.1128/jvi.76.13.6643-6651.2002. J Virol. 2002. PMID: 12050377 Free PMC article.
-
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13. J Virol. 2009. PMID: 19439467 Free PMC article.
-
Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice.Front Cell Infect Microbiol. 2023 Jun 22;13:1191806. doi: 10.3389/fcimb.2023.1191806. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37424774 Free PMC article.
-
Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.Infect Immun. 2001 Apr;69(4):2223-9. doi: 10.1128/IAI.69.4.2223-2229.2001. Infect Immun. 2001. PMID: 11254577 Free PMC article.
-
Intranasal antibody prophylaxis for protection against viral disease.Clin Microbiol Rev. 1999 Jul;12(3):383-93. doi: 10.1128/CMR.12.3.383. Clin Microbiol Rev. 1999. PMID: 10398671 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical